Zenas BioPharma (NASDAQ:ZBIO) & Spruce Biosciences (NASDAQ:SPRB) Critical Analysis

Zenas BioPharma (NASDAQ:ZBIO) and Spruce Biosciences (NASDAQ:SPRB) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their institutional ownership, profitability, analyst recommendations, dividends, valuation, earnings and risk.

Profitability

This table compares Zenas BioPharma and Spruce Biosciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Zenas BioPharma	N/A	-122.45%	-58.04%
Spruce Biosciences	N/A	-123.53%	-90.35%

Analyst Ratings

This is a summary of recent ratings for Zenas BioPharma and Spruce Biosciences, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zenas BioPharma	1	2	6	0	2.56
Spruce Biosciences	1	0	11	0	2.83

Zenas BioPharma currently has a consensus target price of $46.71, suggesting a potential upside of 65.36%. Spruce Biosciences has a consensus target price of $158.33, suggesting a potential upside of 250.37%. Given Spruce Biosciences’ stronger consensus rating and higher possible upside, analysts clearly believe Spruce Biosciences is more favorable than Zenas BioPharma.

Institutional and Insider Ownership

91.7% of Spruce Biosciences shares are held by institutional investors. 22.0% of Zenas BioPharma shares are held by company insiders. Comparatively, 4.3% of Spruce Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares Zenas BioPharma and Spruce Biosciences”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zenas BioPharma	$10.00 million	184.13	-$377.74 million	($8.99)	-3.14
Spruce Biosciences	$4.91 million	26.41	-$38.97 million	($39.78)	-1.14

Spruce Biosciences has lower revenue, but higher earnings than Zenas BioPharma. Zenas BioPharma is trading at a lower price-to-earnings ratio than Spruce Biosciences, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Zenas BioPharma has a beta of -0.88, meaning that its stock price is 188% less volatile than the S&P 500. Comparatively, Spruce Biosciences has a beta of 3.57, meaning that its stock price is 257% more volatile than the S&P 500.

Summary

Spruce Biosciences beats Zenas BioPharma on 7 of the 13 factors compared between the two stocks.

About Zenas BioPharma

Zenas BioPharma, Inc. is a clinical-stage global biopharmaceutical company, which engages in the development and commercialization of transformative immunology-based therapies for patients. The company was founded by Lonnie O. Moulder Jr on November 12, 2019 and is headquartered in Waltham, MA.

About Spruce Biosciences

Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for the treatment of pediatric classic congenital adrenal hyperplasia in children that is in Phase 2 clinical trial; and for females with polycystic ovary syndrome, which is in Phase 2 clinical trial. Spruce Biosciences, Inc. has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses; and collaboration and license agreement with Kaken Pharmaceutical Co. Ltd. to develop, manufacture, and commercialize tildacerfont for the treatment of CAH in Japan. The company was incorporated in 2014 and is headquartered in South San Francisco, California.